EMPREGO DOS BISFOSFONATOS EM ONCOLOGIA VETERINÁRIA
Palavras-chave:
neoplasias ósseas, reabsorção ´óssea, tratamentoResumo
Os bisfosfonatos (BFs) são fármacos utilizados para inibir a reabsorção óssea em diversas enfermidades que envolvem o metabolismo ósseo. Em oncologia são empregados no tratamento de tumores ósseos primários ou metastáticos e no controle da hipercalcemia maligna. Além do efeito sobre a reabsorção óssea, existem trabalhos demonstrado o efeito dos BFs diretamente sobre as células tumorais, com ação citostática, indução de apoptose, inibição da invasividade tumoral, angiogênese e interferência nos processos metastáticos. O objetivo da presente revisão é demonstrar os mecanismos de ação dos bisfosfonatos, as principais aplicações dentro da oncologia veterinária, assim como os possíveis efeitos colaterais do uso destes fármacos.
Referências
Milner RJ, Farese J, Henry CJ. Bisphosphonates and cancer. J Veter Inter Med. 2004;18:597-604.
Vasconcelos DV, Duarte MEL, Maia RC. Efeito anti-tumoral dos bisfosfonatos: uma nova perspectiva terapêutica. Rev Bras Cancerol. 2004;50:45-54.
Grahan R, Russel G. Bisphosphonates: mode of action and pharmacology. Pediatr. 2007;119:150-162.
Fan TM, Lorimier LP, Charney S, Hintermeister JG. Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement. J Vet Intern Med. 2005;19:74-80.
Fan TM. The role of bisphosphonates in the management of patients that have cancer. Vet Clin North Am Small Anim Pract.2007;37:1091-1110.
Fan TM. Intravenous aminobisphosphonates for managing complications of malignant osteolysis in companion animals. Top Companion Anim Med.2009;24(3):151-156.
Hughes DE, Macdonald BR, Russell RG. Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in longterm cultures of human bone marrow. J Clin Invest. 1998;83:1930-35.
Allen MJ. Biochemical markers of bone metabolism in animals: Uses and limitations. Vet Clin Pathol. 2003;32:101-113.
Lucas PW, Fan TM, Garret LD, Griffon DJ Wypij JM. A comparison of five diffrernt bone resorption markers in osteossarcoma-bearing dogs, normal dogs, and dogs with orthopedic diseases. J Vet Intern Med, 2008;22:1008-13.
Ashton JA, Farese JP, Milner RJ. Ambrose LM, Gilder JM. Investigation of the effects of pamidronato disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res. 2005;66(5):885-91.
Fan TM, Lorimier LP, Garrett LD, Lacoste HI. The bone biologic effect of zolendronate in heathy dogs and dogs with malignant osteolysis. J Vet Intern Med, 2008; 22:380-87.
Farese JP, Ashton J, Milner R, Ambrose LL, Gilder JV. The effect of the bisphosphonates alendronate on viability of canine osteossarcoma cells in vitro. In vitro Cell Dev Biol Anim. 2004;40:113-117.
Fan TM, Charney SC, Lorimier LP, Garret LD, Griffon DJ et al. Double-blind placebo controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain. J Vet Intern Med. 2009;23:152-160.
Spugnini EP, Vicenzi B, Caruso G, Baldi A, Citro G et al. Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. J Small Anim Prac. 2009;50:44-46.
Fan TM, Lorimier LP, Odellanderson K, Lacoste HI, Charney SC. Single agente pamidronate for palliative theraphy of canine appendicular osteosarcoma bone pain. J Vet Intern Med. 2007;21:431-439.
Wolfe D, Pillai SPS, Hildreth BE, Lanigan LG, Martin CK et al. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice. Clin Exp Metastasis. 2011;28:377-89.
Wypij JM, Fan TM, Fredrickson RL, Barger AM, Lorimier LP, Charney SC. In vivo and In vitro efficacy of zoledronato for treating oral squamous cell carcinoma in cats. J Vet Intern Med. 2008;22:158-63.
Klein MK. Multimodality therapy for head and neck cancer. Vet Clin North Am Small Anim Pract. 2003;33:615-628
Stebbins KE, Morse CC, Goldschmidt MH. Cat oral neoplasia. A ten year survey. Vet Pathol. 1989;26:121-128
Bregazzi VS, Larue SM, Powers BE, Fettman MJ, Olgivie CK et al. Response of cat oral squamous cell carcinoma to palliative radiation therapy. Vet Radiol Ultrasound. 2001;42:77-79.
Jones PD, Lorimier LP, Kitchell BE, Losonsky JM. Gemcitabine as a radiosensitizer for nonresectable cat oral squamous cell carcinoma. J Am Anim Hosp Assoc. 2003;39:463-67.
Hortobayi GN, Thriault RL, Lipton A. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate: Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol.1998;16:2038-2044.
Theriault RL, Lipton A, Hortobagyi GN. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial—Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol.1999;17:846-854.
Hostutler RT, Chew DJ, Jaeger SK, Klein S, Henderson D, Di Bartola DB. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hipercalcemia. J Vet Intern Med. 2005;19:19-29.
Grill V, Ho P, Body JJ. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metabol.1991;73:1309-1315.
Hafeman SD, Varland D, Dow SW. Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. Vet Comp Oncol. 2012;10(1):44-56.
Webbe-Neville HL, Evans CA, Coleman RE, Holen I. Mechanisms of the Synergistic Interaction between the Bisphosphonate Zoledronic Acid and the Chemotherapy Agent Paclitaxel in Breast Cancer Cells in vitro. Tumor Biol. 2006;27(2):92-103.
Winter MC, Coleman RE. Bisphosphonates in breast cancer: teaching and old dog new tricks. Curr Opin Oncol. 2009;21:499-506.
Poirier VJ, Huelsmeyer MK, Kurzman ID, Thamm DH, Vail DM. The bisphosphonates alendronate and zoledronate are inhibitors of canine and human cell growth in vitro. Vet Comp Oncol. 2003;1(4):207-215.
Santini D, Vicenzi B, Dicuonzo G, Awisati G, Massacesi C, Battistoni F, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893-97.
Ferretti G, Fabi A, Carlini P, Palpado P, Cordiali FP, DiCosimo S, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastática breast cancer patients. Oncol. 2005;69:35-43.
Vicenzi B, Santini D, Dicuonzo, G, Battistoni F, Gavasci M, LaCesa A, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005;25:144-151.
Hafeman SD. Use of liposomal bisphosphonates to deplete macrophages for cancer immunotherapy [dissertação de doutorado]. Fort Collins: Colorado State University. 2011
Orgy B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 2005;104(11):.2522-29.
Higara T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004;10(13):4559-67.
Nobuyuki H, Hiraga T, Williams PJ. The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J Bone Miner Res. 2001;16:191-199.
Saarto T, Blomqvist C, Virkkunen P. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19(1):10-17.
Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335(14):1016-21.
Burr DB, Allen MR. Mandibular necrosis in beagles dogs treated with bisphosphonates. Orthod Craniofac Res. 2009;12:221-228.
Nussbaum SR, Yunger J, Vanderpol CJ. Single dose-intravenous theraphy with pamidronate for the treatment of hypercalcemia: comparison of 30, 60, 90 mg doses. Am J Med. 1993;95:297-300.
Young G, Shende A. Use of pamidronate in the management of acute cancer-related hypercalcemia in children. Med Pediat Oncol. 1998;30:117-21.
Kadan E, Rush JE, Wetmore L, Cahn DL. Eletrolyte disturbances and cardiac arrhythmias in a dog following pamidronate, calcitonin and furosemide andministration for hypercalcemia of malignancy. J Am Anim Hosp Assoc. 2004;40:75-81.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial 4.0 Internacional.
